ImmunityBio (IBRX) Non Operating Investment Income (2020 - 2026)

ImmunityBio (IBRX) has 7 years of Non Operating Investment Income data on file, last reported at $2.3 million in Q1 2026.

• Non Operating Investment Income for Q1 2026 came in at $2.3 million, up 160.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.8 million (up 35.9% YoY), and the FY2025 annual result was $6.4 million, down 19.69% from the prior year.
• Non Operating Investment Income advanced to $2.3 million in Q1 2026 per IBRX's latest filing, from $2.3 million in the prior quarter.
• Over five years, Non Operating Investment Income peaked at $3.1 million in Q1 2024 and troughed at -$3.8 million in Q4 2022.
• A 5-year average of $866764.7 and a median of $1.2 million in 2025 frame the typical range for Non Operating Investment Income.
• The sharpest annual moves came in 2022 and 2024: Non Operating Investment Income tumbled 916.95% in 2022, then jumped 5037.14% in 2024.
• A 5-year view of Non Operating Investment Income shows it stood at -$3.8 million in 2022, then soared by 112.69% to $484000.0 in 2023, then jumped by 145.25% to $1.2 million in 2024, then soared by 93.6% to $2.3 million in 2025, then climbed by 0.7% to $2.3 million in 2026.
• Business Quant data shows IBRX's Non Operating Investment Income at $2.3 million in Q1 2026, $2.3 million in Q4 2025, and $2.1 million in Q3 2025.